not show change ESVLV. The reduction was however significantly greater in gr A (42.4% v. 35.7% p<0.05 WMSI (r=+0.55, p<0.05), E/A (r=-0.52, p<0.01). During 21 days there were 42 end points; 5 (11.9%) in gr A, 11 (26.1%) in gr B, 16 in gr C (38 %).The relative risk reduction (RRR) in end point in gr A was 31% (p=0.01) in comparision to gr B, 35% (p<0.01) to gr C. Conclusion: Combination of A with P and V showed positive effect on ECHO parameters and significantly reduces cardiovascular events.
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Comparative effects of losartan and losartan colchicines combination therapy in unstable angina patients with hyperuricaemia R.S. Gabrielyan 1 ; A.V. Davtyan 1 ; A.B. Gabrielyan 1 1 Ischaemic Heart Disease, Cardiology Dept., Yerevan, Armenia Aims: To investigate the effects of losartan with losartan at the same dose combined with colchicine therapy on ECHO-parameters, on levels of marker of inflammation high -sensivity C reactive protein (hs-CRP), leykocitosis in unstable angina (UA) patients (pts) with hyperuricaemia. To determine the nature of the relathionship between hs-CRP, increased serum uric acid levels, ECHO-parameters, endpoints of pts with UA. Material and methods: 46 pts (age 58.8±0.7) with UA randomly assined to treatment with losartan 50 mg once daily (group I, n=23) or a treatment with losartan at the same dose combined with colchicine 2 mg iv for the first day and then 1mg iv every 6 hour for the second day and 1 mg daily for at least 21 days (group II, n=23). The values of hs-CRP and uric acid were analysed at baseline and at 7 day. 21 days after admission pts underwent echocardiography to determine left ventricular end systolic volume(ESVLV), wall motion score index (WMSI), ejection fraction (EF). The end point was defined as death, recurrent angina or nonfatal MI, need for coronary intervention, whichever occurred in hospitalization. Results: In pts with increased levels of hs-CRP serum uric acid levels were significantly higher than in pts with normal hs-CRP values (p<0.05). Our results show significant decreasing serum uric acid levels at 7 day in groupI (-25.9%±12.1%; p<0.05), decrease in group II was greater (-42.5±11.2%; p<0.01). At 7 days, mean hs-CRP levels was significantly decreased in both group I and group II, but the decrease in group II (-32 
University Hospital of Silesia, 3-rd Depatment of Cardiology, Katowice, Poland
RE vascularization in Ischemic HEart Failure Trial (REHEAT) is a non-randomized, case-control, prospective study to assess the hypothesis that surgical and percutaneous revascularization in patients with ischemic cardiomyopathy are associated with comparable improvement of LVEF and functional status after 12 month from myocardial revascularization. Methods: The study population consisted of 141 patients with LVEF <40% and angiographically confirmed coronary artery disease. Primary end-point was improvement of LVEF 12 months after the intervention. Secondary endpoints were: in-hospital major adverse events (MAE), length of hospitalization, exercise tolerance in ECG treadmill stress test after 12 months, oneyear survival, one-year event-free survival, angina severity and heart failure severity after 12 months. Case-control study included 55 patients in PCI and 54 in CABG group. Results: The incidence of 30 days MAE was higher in CABG group (40.7% vs 9%, p=0.0003). The mean duration of hospital stay was shorter in PCI treatment arm [6.8±3.6 days vs 9.2±2.1 (p=0.00001)]. After 12 month LVEF improved from 31.5±6.2% to 37.5±8.6% in PCI group (p<0.01) and from 33.1±5.1% to 37.5±9.5% in CABG group (p<0.01). The increase was comparable after PCI and CABG (5.96±7.21% vs 4.38±9.04%, p=0.12). Long term functional status based on treadmill stress test was better after PCI (Student's t test, p=0.0003), while according to CCS and NYHA classifications-was similar in both treatment arms (Wilcoxon test, p<0.01). The long-term survival was significantly better in PCI patients ( Wilcoxon test, p<0.01).The MAE free survival was better after CABG (Cox-Manthel test p=0.0013).
Conclusions:
In patients with ischemic cardiomyopathy, PCI is associated with a comparable improvement of LVEF as surgical treatment and offers a better 1-year survival than CABG, however the incidence of repeat revascularization is higher in the PCI group.
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Can we predict acute coronary events by myocardial jeopardy score in patients with natural progression of coronary artery disease Background: Myocardial jeopardy score (MJS) is shown to be a potent predictor of stress induced myocardial ischemia, but its relationship with acute coronary events still remained unknown. Objective: To determine a role of MJS in prediction of acute coronary events (non fatal myocardial infarction and unstable angina pectoris), in patients with natural progression of coronary artery disease (CAD). Methods: We evaluate 88 pts with CAD (73 single vessel, 15 multi vessel), who underwent exercise stress echo test (Ex: maximal Bruce) and who did not undergo revascularization procedure. MJS was calculated as a product of: (1) myocardial segmental kinetic status in a region of significantly stenosed vessel (scored from 1 to 4), (2) percent diameter stenosis (%DS ≥50%, scored from 1 to 5), and (3) weighting flow factor for particular localization of lesion. Results: Follow up period was 46±22 months. Significant univariate predictors of acute coronary events were: MJS, positive Ex and %DS (Table 1) . MJS and %DS showed negative correlation with observed end points. In multivariate Cox regressional analysis, the only independant predictor of coronary events was MJS (p=0.0004). According to ROC curve, value of MJS the best predictive for adverse events was 48.75, and Kaplan-Meier cumulative event free survival analysis showed significantly worse outcomne of pts with MJS≤48.75 in comparison to pts with higher MJS. Conclusion: Patients with lower MJS are in a high risk of acute coronary events in patients with natural progression of coronary artery disease, because of the presence of higher amount of potentially ischemic myocardium and moderate coronary artery stenosis. This confirms the need for integrated evaluation of functional significance of coronary artery disease. Aims: The effect of coronary stent implantation of chronic coronary occlusion on left ventricular (LV) performance is not well known. So, the aim of this study was to assess the effect of stent implantation on LV ejection fraction (EF) and to examine what clinical and angiographic factors may have an effect on recovery of LV EF. Methods and results: Three hundred and four patients who underwent successful stent implantation for chronic occlusion of a major epicardial coronary artery existing for at least six weeks were included into the study. Echocardiographic examination was performed before and six months after stent implantation. A significant increase in LV EF (53.2±11.9% to 57.0±11.1%; p<0.0001) with a decrease in both LV end-diastolic volume index (85.6± ±18.9 ml/m 2 to 80.1±17.1 ml/m 2 ; p<0.001) and LV end-systolic volume index (40.0±15.8 ml/m 2 to 34.1±14.3 ml/m 2 ; p<0.0001) after stent implantation of chronic coronary occlusion was observed. Multivariate analysis revealed diabetes mellitus existence, angiotensin converting enzyme use, occlusion duration <3 month and baseline LV EF<50% to be significant predictors of left LV EF improvement during the first 6 months after stent implantation. Conclusion: Stent implantation for a chronic coronary occlusion has a beneficial effect on LV EF during the first 6 months after the stent implantation, Downloaded from https://academic.oup.com/ehjcimaging/article-abstract/7/suppl_1/S83/2402695 by guest on 23 March 2019
